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Insulin decreases plasma cholesteryl ester transfer but not
cholesterol esterification in healthy subjects as well as in
normotriglyceridaemic patients with type 2 diabetes
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Abstract Background Plasma cholesterol esterification (EST) and subsequent cholesteryl ester
transfer (CET) from high-density lipoproteins (HDLs) towards apolipoprotein (apo) B-
containing lipoproteins are key steps in HDL metabolism.
Materials and methods The effects of exogenous hyperinsulinaemia on plasma CET and
EST, measured with isotope methods, were evaluated in 10 male normotriglyceridaemic
(plasma triglycerides <2·0 mmol L¹1) patients with type 2 diabetes and 10 individually
matched healthy subjects during a two-step hyperinsulinaemic euglycaemic clamp over
6–7 h.
Results No between-group differences in baseline plasma lipid parameters were observed,
but the HDL cholesteryl ester content was lower (P< 0·02) and the HDL triglyceride
content was higher (P <0·05) in diabetic patients. Baseline CETand ESTwere similar in the
groups. In both groups, hyperinsulinaemia decreased plasma triglycerides (P <0·01) and the
HDL triglyceride content (P< 0·01) compared with saline infusion in healthy subjects,
whereas the HDL cholesteryl ester content increased (P <0·05 vs. saline infusion) in diabetic
patients. CET was similarly decreased by hyperinsulinaemia in both groups (P <0·01 vs.
saline infusion). In contrast, the change in EST in either group was not different from that
during saline administration. In the combined group, baseline CETwas positively correlated
with plasma triglycerides (Rs ¼ 0·68, P <0·01). The HDL cholesteryl ester content was
negatively (Rs ¼ ¹0·48, P< 0·05) and the HDL triglyceride content was positively
(Rs ¼ 0·64, P< 0·01) correlated with CET.
Conclusion Insulin infusion decreases plasma CET in conjunction with a fall in triglycer-
ides but does not decrease cholesterol esterification in healthy and type 2 diabetic subjects,
indicating that acute hyperinsulinaemia has a different effect on these processes involved in
HDL metabolism. Despite unaltered fasting plasma CET, HDL core lipid composition was
abnormal in diabetic patients, suggesting that additional mechanisms may contribute to
changes in HDL metabolism in diabetes mellitus.
Keywords Cholesteryl ester transfer, cholesterol esterification, free fatty acids, high-density
lipoproteins, insulin, triglycerides, type 2 diabetes mellitus.
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Introduction
The process of reverse cholesterol transport, whereby
cholesterol is transported from peripheral tissues back to
the liver for excretion and conversion to bile acids, is
regarded as representing an important defence mechanism
against atherosclerosis development [1–4]. This pathway
consists of several metabolic steps, including uptake of
unesterified cholesterol from cell surfaces by extracellular
acceptors such as pre-b high-density lipoproteins (HDLs)
and subsequent cholesterol esterification by lecithin cho-
lesterol acyltransferase (LCAT) [2–7]. HDL cholesteryl
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esters can then be taken up by the liver by various mechan-
isms [3,4,8,9]. In man, HDL cholesteryl esters are also
transferred to very low- and low-density lipoproteins
(VLDLs and LDLs) by the cholesteryl ester transfer
protein (CETP), and uptake of these apolipoprotein
(apo) B-containing lipoproteins by the liver provides an
additional route for hepatic delivery of cholesterol originat-
ing from HDL [4,10,11].
Despite continued controversy [12–15], there is recent
epidemiological evidence supporting the hypothesis that
hyperinsulinaemia is a cardiovascular risk factor [16]. The
effects of insulin on reverse cholesterol transport are
incompletely understood. Insulin may inhibit cellular
cholesterol efflux in vitro [17,18], as well as cholesterol
uptake in hepatic cells, either directly [18] or by lowering
hepatic lipase activity [19]. Little is known about the effects
of insulin on plasma cholesterol esterification and (CET).
These processes are not only governed by the plasma levels
of LCAT and lipid transfer proteins, but are to an impor-
tant extent also positively related to the plasma triglyceride
concentration [10,20–22]. Because insulin acutely lowers
plasma triglycerides [23–25], it is plausible to postulate
that these processes could be influenced by exogenous
hyperinsulinaemia. In type 2 diabetic patients with ade-
quate metabolic control, plasma cholesterol esterification
has been reported to be unaltered [26,27] or increased
[22]. Plasma CET has been found to be decreased [28],
unchanged [27] or increased [22,26,29,30]. These equi-
vocal results may, at least in part, be attributed to selection
of subjects, with hypertriglyceridaemic type 2 diabetic
patients showing increased plasma cholesterol esterifica-
tion [22] and CET [22,30].
The purpose of the present report was to compare the
effects of exogenous hyperinsulinaemia on plasma CET
and cholesterol esterification in type 2 diabetic patients and
healthy subjects. The type 2 diabetic and healthy subjects
were individually matched for fasting plasma triglycerides,
and only normotriglyceridaemic individuals participated to
minimize confounding effects of dyslipidaemia on these
processes.
Methods
The present study was approved by the medical ethics
committee of the University Hospital Groningen, and all
participants provided written informed consent. In
healthy subjects, diabetes mellitus was excluded by a
glucose tolerance test with fasting venous blood glucose
$ 6·7 mmol L¹1 and a 2-h post-load glucose
$ 10·0 mmol L¹1 as cut-off levels [31]. Type 2 diabetes
mellitus was diagnosed according to National Diabetes
Data group criteria [31]. Age at onset of diabetes was
> 40 years, and none of the patients was treated with
insulin. Only non-smoking men participated to avoid the
effects of smoking [32,33] and the menstrual cycle [34] on
lipid levels. Fasting plasma triglycerides $ 2·0 mmol L¹1,
total cholesterol $ 6·5 mmol L¹1, severe obesity, defined as
a body mass index (BMI, calculated as weight divided by
height squared) >30 kg m¹2, clinically manifest cardio-
vascular disease, hypertension (systolic blood pressure
> 160 mmHg and diastolic blood pressure >90 mmHg),
thyroid, kidney and liver dysfunction, alcohol use > 3
drinks per day and the use of medication other than oral
glucose-lowering agents were exclusion criteria. The type 2
diabetic patients were individually matched with healthy
subjects for age (within 5 years), BMI (within 1 kg m¹2)
and fasting plasma triglycerides (within 0·5 mmol L¹1).
The study subjects continued their habitual diet and the
type 2 diabetic patients took their glucose-lowering drugs
until the study day. Alcohol consumption was avoided on
the day before the study, and the participants fasted from
20.00 h onwards. They were in the supine position after
08.00 h. A hand vein was cannulated and the catheter was
kept patent with a saline drip. (NaCl, 154 mmol L¹1,
30 mL h¹1). This hand was placed in a thermoregulated
box with an ambient temperature of 558C in order to obtain
arterialized venous blood. A contralateral antecubital vein
was used for infusion of glucose (20% by volume, to which
potassium chloride 20 mmol per litre of glucose was added
to prevent hypokalaemia) and insulin. Baseline blood
samples were taken after 1 h of supine rest. Thereafter, a
two-step hyperinsulinaemic, euglycaemic clamp was
started. Insulin was infused at a rate of 30 mU kg¹1 h¹1
and of 150 mU kg¹1 h¹1, with the first step lasting 3 h (4 h
in diabetic patients) and the second step lasting 3 h. Each
step was primed by an insulin bolus of 5 mU kg¹1. Blood
glucose was maintained at 4·6 mmol L¹1 by varying the
glucose infusion. To be able to compare possible changes in
parameters due to a dilutional effect of glucose infusion or
to a time effect with the effects of insulin, the healthy
subjects were restudied within 4 weeks, receiving
1200 mL of saline (NaCl, 154 mmol L¹1) over 6 h. This
volume was similar to the mean volume infused in healthy
subjects during the hyperinsulinaemic clamp.
Laboratory measurements
Blood was collected into EDTA-containing tubes
(1·5 mg mL¹1) and was directly placed on ice. Plasma
was obtained within 30 min by low-speed centrifugation
for 15 min at 48C. Samples were kept frozen at ¹708C and
analysed within 2 months.
Plasma CET was measured by a radioisotope method
essentially as described previously [35]. In brief, a tracer
amount of [3H]-cholesterol, complexed to albumin, was
incubated overnight at 48C with 0·3 mL of the individual
plasma samples to be analysed. The tracer contained
150 000 dpm and 3 nmol of unesterified cholesterol. After
this incubation, an equilibrium is reached between the
labelled unesterified cholesterol and the unesterified cho-
lesterol present in the plasma sample, i.e. the specific
radioactivity of unesterified cholesterol is the same in all
lipoprotein classes (VLDL, LDL and HDL). This specific
radioactivity is determined by measuring plasma unester-
ified cholesterol mass. Subsequently, the plasma samples
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were incubated at 378C for 3 h. During this incubation
radioactive cholesteryl esters are formed on HDL by the
LCAT reaction, and these newly synthesized cholesteryl
esters are distributed by CETP among the various acceptor
lipoprotein particles (VLDL, LDL, HDL). To measure
CET, i.e. the transfer of cholesteryl esters to VLDL and
LDL, these lipoproteins are precipitated from the
incubation mixture after the 3 h incubation at 378C by
addition of phosphotungstate/MgCl2. The precipitate is
then collected by low-speed centrifugation, washed once
with phosphotungstate/MgCl2 solution, collected again
and suspended in 0·2 mL of saline. The cholesteryl esters
are extracted with 0·3 mL of methanol þ 0·4 mL of hexane
by vortexing the mixture. Separation of the hexane phase
from the methanol–saline phase is achieved by low-speed
centrifugation. Subsequently, the hexane is applied to a
silica column. Another 0·4 mL of hexane is added to the
methanol–saline phase and the procedure is repeated. The
second hexane fraction is applied to the same silica column.
Radioactive unesterified cholesterol, which is also present
to some extent in the hexane phase, is separated from the
labelled cholesteryl esters by elution with 3 mL of hexane–
diethylether (6:1, v/v). Unesterified cholesterol remains
bound to the silica, whereas the cholesteryl esters are
eluted [36]. The accumulation of labelled cholesteryl
esters in LDL and VLDL is linear with time during
the whole incubation period. CET is calculated using the
specific radioactivity of cholesteryl esters present in the
incubation mixtures as described [35]. The chemical com-
position of the substrate lipoproteins in this assay reflects
the actual situation in vivo at the time of blood sampling.
The rate of distribution of newly formed cholesteryl esters
to VLDL and LDL is closely correlated with the net
cholesteryl ester mass transfer from HDL to VLDL and
LDL under conditions of LCAT inhibition, so that the
CET assay can be regarded as an accurate estimate of
cholesteryl ester mass transfer in plasma [30]. The influ-
ence of the minor cholesterol esterification in LDL (<4%
of total) can be ignored for the CET assay [35].
Cholesterol esterification in total plasma (EST) was
assayed as described previously [35], using the same
incubation system as for the CET assay. After incubation
for 1 h at 378C, cholesteryl esters are extracted with hexane
from the complete incubation mixture and radioactive
unesterified cholesterol is separated from the labelled
cholesteryl esters on the silica columns system. The
cholesterol esterification rate is linear with time for 5 h,
indicating an excess of unesterified cholesterol in the assay
system [35]. CET and EST assays were performed using
the same batches of [3H]-cholesterol–albumin complex, all
assays were performed in duplicate, and the CETand EST
measurements are expressed in nmol mL¹1 h¹1. The
within-assay coefficients of variation of plasma CET and
EST are 7·1% and 5·4% respectively.
Lipids were measured in plasma and in the HDL frac-
tion after precipitation of apolipoprotein (apo) B-contain-
ing lipoproteins with polyethylene glycol-6000 [37]. VLDL
þ LDL were calculated as the difference between plasma
and the supernatant fraction. Total cholesterol and free
cholesterol were measured by gas chromatography.
Cholesteryl ester was calculated as the difference between
total and free cholesterol. Triglycerides and phospholipids
were measured as described [38]. ApoAI and ApoB
were measured by immunoturbidimetry (Boehringer
Mannheim, Germany, cat. nos 726478 and 726494,
respectively). Plasma free fatty acids (FFA) were measured
Table 1 Clinical characteristics, blood glucose and plasma insulin at baseline and
during the hyperinsulinaemic clamp in type 2 diabetic patients and healthy subjects
Type 2 diabetic patients Healthy subjects
(n ¼ 10) (n ¼ 10)
Age (years) 53 6 8 54 6 9
Diabetes duration (years) 9 6 8 –
Body mass index (kg m–2) 25·8 6 2·6 25·7 6 2·9
Waist–hip ratio 0·97 6 0·04 0·94 6 0·09
Blood pressure
systolic/diastolic (mmHg) 131 6 14/83 6 7 133 6 8/85 6 4
Alcohol (U day¹1) 0·6 6 0·9 0·6 6 1·0
HbA1c (%) 7·5 6 1·5* 5·5 6 0·7
Blood glucose (mmol L¹1)
Baseline 8·3 6 1·1* 5·3 6 0·4
First insulin step 4·4 6 0·2‡ 4·7 6 0·3†
Second insulin step 4·5 6 0·2‡ 4·8 6 0·3†
Plasma insulin (mU L¹1)
Baseline 10 6 5 12 6 3
First insulin step 31 6 6‡ 31 6 8‡
Second insulin step 170 6 26‡ 163 6 46‡
Data are means 6 SD. Blood glucose levels at the last hour of each insulin step
and plasma insulin concentrations at the end of each insulin step are given.
*P <0·01 compared with healthy subjects. †P <0·05, ‡P <0·001 campared with
baseline.
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using a kit from Wako (Germany, cat. no. 994-754-75409).
Blood glucose was analysed on an APEC Glucose Analyser
(Apec, Danvers, MA, USA). Glycated haemoglobin
(HbA1c) was measured by high-performance liquid chro-
matography (Bio-Rad, Veenendaal, The Netherlands;
normal range 4·6–6·1%).
Statistical analysis
Data are expressed as means 6 SD, unless stated otherwise.
Baseline parameters in healthy subjects and type 2 diabetic
patients were compared by unpaired Wilcoxon tests.
Between-group differences in changes in parameters after
insulin and saline administration were evaluated by
Kruskal–Wallis analysis of variance. Within-group changes
in parameters after insulin and saline infusion were
analysed by Friedman’s two-way analysis of variance.
Duncan’s method was applied to correct for multiple
comparisons. Bivariate correlations were evaluated by
Spearman’s rank correlation analysis (Rs). A two-sided
P-value<0·05 was considered significant.
Results
As shown in Table 1, there were no differences in age, BMI,
waist–hip ratio, blood pressure and alcohol intake between
the diabetic patients and healthy subjects. One of the
diabetic patients was treated with diet alone, four were
treated with diet plus sulphonylurea, and five were treated
with diet in combination with sulphonylurea and metfor-
min. HbA1c and baseline blood glucose were higher in
diabetic patients. Plasma insulin levels were not different
between the groups. During the clamp blood glucose
reached target levels in each group and plasma insulin
rose similarly in diabetic and healthy subjects.
Table 2 demonstrates that there were no differences in
baseline plasma total cholesterol, triglycerides, VLDL þ
LDL cholesterol, apoAI, apoB and FFAs between the
groups. HDL-cholesterol was not significantly different
between the groups, but the HDL cholesteryl ester content
was lower and the HDL triglyceride content was higher in
diabetic patients than in the healthy subjects. Plasma CET
and EST were not different between the groups.
During the hyperinsulinaemic clamp, plasma triglycer-
ides decreased similarly in diabetic and healthy subjects. In
both groups, the fall was significantly larger than the
change during the saline infusion experiment that was
carried out in healthy subjects (Fig. 1a). HDL-cholesterol
decreased during hyperinsulinaemia in diabetic and healthy
subjects, as well as during saline administration (Fig. 1b).
In diabetic patients, the decrease in HDL-cholesterol
during hyperinsulinaemia was smaller than that during
saline infusion, whereas in healthy subjects the difference
in change in HDL-cholesterol compared with saline infu-
sion did not reach significance (P< 0·10). Compared with
saline infusion, hyperinsulinaemia resulted in an increase in
the HDL cholesteryl ester content (expressed in mol% of
total lipids) in diabetic patients. In healthy subjects, the
change in the HDL cholesteryl ester content after insulin
was not significantly different (P ¼ 0·10) from the change
during saline infusion (Fig. 1c). The HDL triglyceride
content decreased in both groups compared with saline
infusion (Fig. 1d). Plasma FFAs decreased during hyper-
insulinaemia in both groups, whereas prolonged fasting
during the saline experiment was accompanied by an
increase in plasma FFAs (Fig. 1e). During hyperinsulinae-
mia plasma apoB decreased in diabetic and healthy subjects
compared with saline infusion (Fig. 1f). A decrease in
plasma apoAI during hyperinsulinaemia was observed in
both groups, but its change was not different from the
change during saline infusion (P >0·10 for diabetic and
healthy subjects, data not shown).
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Table 2 Baseline plasma (apo) lipoproteins, high-density lipoprotein (HDL) lipid
composition, free fatty acids, cholesteryl ester transfer (CET) and cholesterol esterification
rate (EST) in type 2 diabetic patients and healthy subjects
Type 2 diabetic patients Healthy subjects
(n ¼ 10) (n ¼ 10)
Plasma total cholesterol (mmol L¹1) 4·89 6 0·67 5·06 6 0·71
Plasma triglycerides (mmol L¹1) 1·26 6 0·41 1·06 6 0·28
VLDL þ LDL-cholesterol (mmol L¹1) 3·79 6 0·83 3·85 6 0·90
HDL cholesterol (mmol L¹1) 1·09 6 0·30 1·22 6 0·28
Apolipoprotein AI (g L¹1) 1·24 6 0·24 1·27 6 0·15
Apolipoprotein B (g L¹1) 0·94 6 0·20 0·86 6 0·22
HDL cholesteryl ester (mol%) 37·9 6 3·3† 42·5 6 4·8
HDL triglycerides (mol%) 8·4 6 2·6* 6·1 6 1·7
HDL free cholesterol (mol%) 7·4 6 1·4 6·4 6 2·0
HDL phospholipids (mol%) 46·3 6 4·4 44·9 6 3·5
Plasma free fatty acids (mmol L¹1) 587 6 137 490 6 83
Plasma CET (nmol mL¹1 h¹1) 22·8 6 10·4 22·1 6 9·7
Plasma EST (nmol mL¹1 h¹1) 72·4 6 23·1 65·2 6 18·0
Data are means 6 SD.
*P <0·05, †P <0·02 from healthy subjects.
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Plasma CET was similarly decreased by hyperinsulin-
aemia in both groups. Its decrement in diabetic and healthy
subjects was larger than that during saline infusion
(Fig. 2a). In contrast, the decrease in plasma EST that
occurred in diabetic and healthy subjects was not
different from its decrement during saline infusion
(Fig. 2b).
Baseline plasma CET was positively correlated with
plasma triglycerides (Rs ¼ 0·68, P< 0·01, in combined sub-
jects; Rs ¼ 0·82, P <0·01, in healthy subjects, Rs ¼ 0·51, NS
in diabetic patients). Baseline plasma EST was also related
to plasma triglycerides (Rs ¼ 0·52, P <0·05, in combined
subjects), but its correlation did not reach significance in
the separate groups. No relationships of baseline plasma
CETand ESTwith plasma FFAs were observed (Rs ¼ 0·08,
NS, and Rs ¼ ¹0·15, NS, in combined subjects respec-
tively). The HDL cholesteryl ester content at baseline was
negatively correlated with plasma CET (Rs ¼ ¹0·48,
P <0·05, in combined subjects; Rs ¼ ¹0·71, P <0·05, in
healthy subjects; Rs ¼ ¹0·35, NS, in diabetic patients). The
baseline HDL triglyceride content was positively correlated
with plasma CET (Rs ¼ 0·64, P <0·01, in combined
subjects; Rs ¼ 0·78, P< 0·02, in healthy subjects;
Rs ¼ 0·52, NS, in diabetic patients).
Discussion
The present study has shown that plasma CETand ESTare
unaltered in normotriglyceridaemic type 2 diabetic patients
compared with normolipidaemic healthy subjects. Despite
exclusion of hypertriglyceridaemic subjects, plasma CET
and EST were positively correlated with plasma trigly-
cerides in the combined subjects. This finding supports
the notion that even a normal plasma triglyceride-rich
lipoprotein level is a determinant of plasma CET as well
as of EST. It was anticipated that the hyperinsulinaemic
euglycaemic clamp induced haemodilution, necessitating
the comparison of changes in lipoprotein parameters after
insulin with those observed after volume expansion.
Indeed, significant decreases in plasma triglycerides,
HDL-cholesterol, CET and EST were observed during
saline infusion in healthy subjects. A potentially important
Figure 1 Changes in plasma triglycerides (a), high-density
lipoprotein (HDL)-cholesterol (b), HDL cholesteryl ester
content (c), HDL triglyceride content (d), plasma free fatty acids
(e) and plasma apo B (f) in response to hyperinsulinaemia in
type 2 diabetic patients (B), in healthy subjects (W) and during
saline infusion in healthy subjects (D). b Indicates baseline, 18
and 28 indicate measurements after 3 (4) h of insulin infused
at 30 mU kg¹1 h¹1, respectively, and after 3 h of insulin infused
at 150 mU kg¹1 h¹1. Data are means 6 SEM. *P <0·05,
†P <0·01, ‡P <0·001 compared with baseline. §P <0·05,
¶P <0·01 compared with overall change during saline infusion in
healthy subjects.
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novel finding of our study was that exogenous hyper-
insulinaemia compared with the saline infusion experiment
decreased plasma CET similarly in normotriglyceridaemic
type 2 diabetic patients and in healthy subjects. Compared
with saline infusion, insulin administration did not affect
plasma EST in either group. Hence, the present data
suggest that acute hyperinsulinaemia has a different
effect on plasma CET in comparison with cholesterol
esterification.
By the process of CET, cholesteryl esters are transferred
from HDL towards lipoproteins of lower density classes,
whereas triglycerides are transferred in the opposite direc-
tion [10,11]. The rate of CET is governed not only by the
composition and concentration of cholesteryl ester donor
and acceptor lipoproteins [10,20,28], but also by the
amount of active CETP [22,39]. Another lipid transfer
protein, phospholipid transfer protein (PLTP), may
enhance the CETP-mediated CET [22,40]. Furthermore,
in vitro experiments have shown that CET from HDL
towards VLDL is stimulated during lipolysis as a conse-
quence of accumulation of fatty acids in VLDL remnants
[41,42]. It is likely that the decrease in plasma CET during
hyperinsulinaemia can be attributed mainly to a decrease in
plasma triglycerides, reflecting a lowered cholesteryl ester
acceptor lipoprotein concentration. In addition, a decrease
in plasma PLTP activity [25,43] could contribute to the
lower plasma CETafter insulin. Although a small decrease
in plasma CETP activity, as a measure of CETP mass, has
been reported in response to insulin infusion in non-
diabetic subjects [44], no such effect was found during
endogenous [25] and exogenous [43] hyperinsulinaemia in
our earlier studies. Thus, it seems unlikely that changes in
the plasma CETP level per se are important in this lowering
of plasma CET. Of note, the current experiments challenge
the possible effect of the ambient plasma FFA level on
plasma CET and its fall during hyperinsulinaemia. Firstly,
baseline plasma CET was not correlated with plasma FFA.
This finding is in accord with other studies [25,43] but
differs from the positive correlation between plasma FFA
and CET from HDL towards VLDL and LDL, observed in
a group of normolipidaemic individuals, which included
subjects with very high fasting plasma FFA levels [42].
Secondly, changes in plasma FFA and CET were disso-
ciated during saline infusion, as plasma FFA increased,
whereas plasma CET decreased, probably because of
plasma dilution.
The process of CET provides a plausible metabolic
intermediate to explain the negative relationship of HDL
cholesterol and HDL cholesteryl ester content to plasma
triglycerides [10,45]. Indeed, the HDL cholesteryl ester
content was negatively correlated with plasma CET,
whereas the HDL triglyceride content was positively cor-
related with plasma CET. These relationships should be
regarded as effects of CET and reciprocal triglyceride
transfer on HDL core lipids [46], rather than as support
of the possibility that cholesteryl ester depletion and trigly-
ceride enrichment of HDL is a primary abnormality that
causes a reduction in CET out of HDL [26,28,47]. In
keeping with this view, we propose that the decrease in
plasma CET coinciding with the fall in triglycerides pro-
vides a mechanism for the lack of decrease in HDL-
cholesterol [23] and in the HDL cholesteryl ester content,
as well as for the decrease in the HDL triglyceride content
in response to acute hyperinsulinaemia. Obviously, we
cannot exclude contributions of other mechanisms to
these changes in HDL core lipids during hyperinsulinae-
mia, but it seems unlikely that the reported decrease in
hepatic lipase activity [19] is primarily responsible because
this would result in an increase rather than a decrease in the
HDL triglyceride content.
Our study confirms that plasma cholesterol esterification
in total plasma is positively correlated with plasma
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Figure 2 Changes in plasma cholesteryl ester transfer (CET, a)
and cholesterol esterification rate (EST, b) in response to
hyperinsulinaemia in type 2 diabetic patients (B), in healthy
subjects (W) and during saline infusion in healthy subjects (D).
b Indicates baseline, 18 and 28 indicate measurements after 3
(4) h of insulin infused at 30 mU kg¹1 h¹1, respectively, and after
3 h of insulin infused at 150 mU kg¹1 h¹1. Data are
means 6 SEM. *P<0·05, †P<0·01, ‡P <0·001 compared with
baseline. §P <0·01 compared with overall change during saline
infusion in healthy subjects.
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triglycerides [21,22]. Consequent to the process of CET
and the actions of lipases, HDL particle size and choles-
teryl ester content are inversely related to plasma trigly-
cerides [10,45]. Because LCAT preferentially interacts
with small, cholesteryl ester-poor HDL [21,45], the
positive relationship between plasma triglycerides and
EST is probably explained by an effect of triglycerides on
HDL composition. The fall in plasma ESTafter insulin was
not different from that during saline infusion. This lack of
effect of acute hyperinsulinaemia on plasma EST as
opposed to the decrease in plasma CET is of interest,
because plasma cholesterol esterification and CET are
thought to be integrated processes [48]. The mechanisms
responsible for the absence of a change in plasma ESTafter
insulin are unknown.
The unaltered plasma CET [22,27,30] and cholesterol
esterification [22,27,49] in type 2 diabetic patients com-
pared with triglyceride-matched healthy subjects is in
agreement with other studies. However, a decrease in
plasma CET was originally reported in severely hyper-
glycaemic type 2 diabetic patients [50]. Some studies, in
contrast, showed an increase in CET out of HDL in
diabetic plasmas, in association with abnormalities in
VLDL composition, apart from its triglyceride content
[26,29]. Despite unchanged plasma CET and EST, HDL
was found to be cholesteryl ester poor and triglyceride rich
[51] in normotriglyceridaemic type 2 diabetic patients.
This finding indicates that, besides CET and cholesterol
esterification, measured in the fasting state, additional
mechanisms contribute to an abnormal HDL core lipid
composition in the diabetic state. An elevated post-prandial
triglyceride-rich lipoprotein response has been observed in
type 2 diabetic patients compared with healthy subjects
matched for fasting plasma triglycerides [52]. This could
result in sustained alterations in HDL composition in
fasting plasma from diabetic patients as observed in the
present study.
Although the process of CET in plasma is part of the
reverse cholesterol transport pathway in man, this does not
necessarily imply that inhibition of plasma CET represents
a proatherogenic effect of insulin. In fact, accelerated
plasma CET has been documented in dyslipidaemic con-
ditions associated with an increased cardiovascular risk
[22,26,39,53]. On the other hand, epidemiological studies
suggest that subjects with partial genetic CETP deficiency
have an increased cardiovascular risk [54]. It could be
possible that the consequence for atherogenesis of a low-
ering in plasma CET by insulin is dependent on the balance
between hepatic catabolism of apoB-containing lipo-
proteins and the efficacy of non-CET routes for cholesterol
delivery to the liver [55,56].
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